| Stevanato Group to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 6, 2025 |
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2024 on Thursday, March 6, 2025, at 6:30 a.m.(ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, March 6, 2025,. |
businesswire.com |
2025-02-24 18:02:00 |
Czytaj oryginał (ang.) |
| USNA or STVN: Which Is the Better Value Stock Right Now? |
Investors interested in Medical - Drugs stocks are likely familiar with USANA Health Sciences (USNA) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2025-02-14 14:46:35 |
Czytaj oryginał (ang.) |
| USNA vs. STVN: Which Stock Is the Better Value Option? |
Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2025-01-29 14:40:29 |
Czytaj oryginał (ang.) |
| UTHR vs. STVN: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Medical - Drugs sector have probably already heard of United Therapeutics (UTHR) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors? |
zacks.com |
2025-01-08 14:55:48 |
Czytaj oryginał (ang.) |
| Stevanato Group to Present at Upcoming Investor Conference |
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the CJS Securities 25th Annual “New Ideas for the New Year” Investor Conference on Tuesday, January 14, 2025, at 8:00 a.m. ET. A live event webcast will be available on the Company's website at www.stevanatogroup.com under the "Investors" sec. |
businesswire.com |
2025-01-07 18:30:00 |
Czytaj oryginał (ang.) |
| Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement |
Q3 2024 sales exceeded estimates, but adj. EBITDA and EPS fell short due to under-utilization and higher costs in the Engineering division. Despite temporary headwinds, we expect sequential margin improvement thanks to high-value solutions and new facilities ramp-up. Long-term growth remains strong, and Stevanato's economic moat remains intact. Looking ahead, we decided to maintain our buy rating target. |
seekingalpha.com |
2024-11-13 03:18:27 |
Czytaj oryginał (ang.) |
| Stevanato Group to Present at Upcoming Investor Conferences |
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences. The Company will participate in a fireside chat at the UBS Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday, November 12, 2024 at 11:00 a.m. (PT). The Company will also present at. |
businesswire.com |
2024-11-11 08:32:00 |
Czytaj oryginał (ang.) |
| CPRX vs. STVN: Which Stock Is the Better Value Option? |
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-11-06 14:45:45 |
Czytaj oryginał (ang.) |
| Stevanato Group S.p.A. (STVN) Q3 2024 Earnings Call Transcript |
Stevanato Group S.p.A. (NYSE:STVN ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Lisa Miles - Senior Vice President & Investor Relations Franco Stevanato - Chairman & Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Larry Solow - CJS Securities Patrick Donnelly - Citi Jacob Johnson - Stephens Dave Windley - Jefferies Paul Knight - KeyBanc Capital Markets Dan Leonard - UBS Curtis Moiles - BNP Paribas Exane Operator Good afternoon. |
seekingalpha.com |
2024-11-05 16:10:52 |
Czytaj oryginał (ang.) |
| Stevanato Group (STVN) Q3 Earnings Match Estimates |
Stevanato Group (STVN) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.16 per share a year ago. |
zacks.com |
2024-11-05 10:51:12 |
Czytaj oryginał (ang.) |
| Stevanato Group to Report Third Quarter 2024 Financial Results on November 5, 2024 |
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, November 5, 2024, to discus. |
businesswire.com |
2024-10-22 20:30:00 |
Czytaj oryginał (ang.) |
| Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for |
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-22 15:05:39 |
Czytaj oryginał (ang.) |
| CPRX or STVN: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2024-10-21 16:45:25 |
Czytaj oryginał (ang.) |
| CPRX or STVN: Which Is the Better Value Stock Right Now? |
Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors? |
zacks.com |
2024-10-04 16:41:10 |
Czytaj oryginał (ang.) |
| Stevanato Group Will Introduce Its Large-Volume Vertiva® 10mL On-Body Delivery System Platform for Injectable Therapies at CPHI Milan |
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, announced today the expansion of its Vertiva® platform, which will include a 10mL option to be presented at CPHI Milan in October. The Vertiva® easy-to-use platform can be pre-programmed to accommodate different motor driven dosing profiles, from micro-precision basal delivery to full-c. |
businesswire.com |
2024-10-01 10:30:00 |
Czytaj oryginał (ang.) |
| Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU” |
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, together with Gerresheimer AG (MDAX: GXI) and SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP), announced today that they have entered into a strategic industry alliance ("Alliance for RTU") to support market adoption of Ready-to-Use (RTU) vials and cartridges. The Alliance. |
businesswire.com |
2024-09-26 11:04:00 |
Czytaj oryginał (ang.) |
| Stevanato Group to Present at Upcoming Investor Conferences |
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences. The Company will present at the Morgan Stanley Healthcare Conference in New York on Friday, September 6, 2024 at 7:00 a.m. (ET), and at the Bank of America Global Healthcare Conference in L. |
businesswire.com |
2024-08-29 20:30:00 |
Czytaj oryginał (ang.) |
| SDZNY vs. STVN: Which Stock Is the Better Value Option? |
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-08-12 16:47:20 |
Czytaj oryginał (ang.) |
| Stevanato Group S.p.A. (STVN) Q2 2024 Earnings Call Transcript |
Stevanato Group S.p.A. (STVN) Q2 2024 Earnings Call Transcript |
seekingalpha.com |
2024-08-10 13:09:09 |
Czytaj oryginał (ang.) |
| Stevanato Group (STVN) Q2 Earnings Match Estimates |
Stevanato Group (STVN) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.15 per share a year ago. |
zacks.com |
2024-08-06 12:50:52 |
Czytaj oryginał (ang.) |
| Stevanato Group Reports Financial Results for the Second Quarter of 2024 |
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue for the second quarter of 2024 increased 2% to €259.6 million, compared with the same period last year, and high-value solutions represented 40% of total reven. |
businesswire.com |
2024-08-06 10:31:00 |
Czytaj oryginał (ang.) |
| Stevanato Group S.p.A. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - STVN |
NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws. |
accesswire.com |
2024-07-26 11:30:00 |
Czytaj oryginał (ang.) |
| STVN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Stevanato Group S.p.A. Shareholders Who Lost Money |
NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws. |
accesswire.com |
2024-07-25 11:30:00 |
Czytaj oryginał (ang.) |
| Stevanato Group to Report Second Quarter 2024 Financial Results on August 6, 2024 |
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the second quarter of 2024 on Tuesday, August 6, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, August 6, 2024, to discuss f. |
businesswire.com |
2024-07-25 10:30:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of an Investigation into Stevanato Group S.p.A. (STVN) Regarding Potential Securities Fraud Allegations |
NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws. |
accesswire.com |
2024-07-24 11:30:00 |
Czytaj oryginał (ang.) |